Dasatinib price after insurance

The original drug Dasatinib (Dasatinib) has been launched in China and has been included in medical insurance. Currently, reimbursement is only available to eligible patients. The price of a common specification of 50mg*60 tablets per box may be around 10,000 yuan. The reimbursement ratio is different in different regions. The price after reimbursement may be different. Patients can consult the local medical insurance bureau or hospital to learn more.

Specifically, the U.S. Food and Drug Administration (FDA) approved dasatinib for the treatment of adults with newly diagnosed chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), or adults with Ph+ CML who are no longer benefiting from or intolerant to other treatments, including imatinib mesylate, or who have Ph+ acute lymphoblastic leukemia (Ph+ Adults 1 year and older with ALL) who no longer benefit from or cannot tolerate other treatments, or children 1 year and older with chronic phase Ph+CML, and children 1 year and older with newly diagnosed Ph+ ALL and receiving chemotherapy.

The active substance in dasatinibdasatinib belongs to a group of drugs that block protein kinases and mainly works by blocking the BcrAbl protein kinase. This enzyme is produced by leukemia cells and causes them to multiply uncontrollably. By blocking Bcr Abl kinase, as well as other kinases, dasatinib helps reduce the number of leukemia cells.

The overseas original drug of dasatinib is more expensive. Dasatinib generics are also sold overseas. The ingredients of the drug are basically the same as those sold domestically and abroad, but the price is cheaper. For example, the price of a box of 50mg*60 tablets produced by an Indian pharmaceutical factory may be several hundred yuan (the price may fluctuate due to exchange rates).